Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leishmaniasis: current situation and new perspectives.

P Desjeux1

  • 1Department of Control, Prevention and Elimination (CDS/CPE), Cluster of Communicable Diseases, World Health Organization (WHO), Avenue Appia, 1211 Geneva 27, Switzerland. desjeuxp@who.int

Comparative Immunology, Microbiology and Infectious Diseases
|July 1, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2007
Same author

Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.

Annals of tropical medicine and parasitology·2006
Same author

[Therapeutic options for visceral leishmaniasis].

Medecine et maladies infectieuses·2005
Same author

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2004
Same author

Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal.

Tropical medicine & international health : TM & IH·2004
Same author

Treatment of cutaneous leishmaniasis among travellers.

The Journal of antimicrobial chemotherapy·2004

Leishmaniasis, a disease affecting millions globally, requires improved control tools. New diagnostics, drugs, and vaccines are being developed to combat visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL) epidemics.

Area of Science:

  • Neglected tropical diseases
  • Parasitology
  • Epidemiology

Background:

  • Leishmaniasis presents diverse clinical and epidemiological forms, with visceral leishmaniasis (VL) being fatal if untreated and anthroponotic foci causing severe epidemics.
  • The global burden of leishmaniasis is substantial, impacting 88 countries and 350 million people, with significant annual new cases of VL and CL, and millions of DALYs.
  • Environmental factors (migration, urbanization, deforestation) and individual risk factors (HIV, malnutrition) contribute to the persistent public health challenge of leishmaniasis.

Purpose of the Study:

  • To highlight the critical need for enhanced control tools for leishmaniasis.
  • To emphasize the World Health Organization/TDR's focus on developing new diagnostic tests, drugs, and vaccines for leishmaniasis.
  • To underscore the potential for significant impact on mortality, morbidity, and transmission in anthroponotic foci with new control strategies.

Related Experiment Videos

Main Methods:

  • Review of current leishmaniasis epidemiology and burden.
  • Analysis of risk factors contributing to disease prevalence.
  • Overview of World Health Organization/TDR research and development efforts.

Main Results:

  • Significant global burden of leishmaniasis with clear geographic priorities identified.
  • Ongoing research yielding promising new control tools, including diagnostics, drugs, and vaccines.
  • Feasibility of achieving substantial impact on leishmaniasis mortality, morbidity, and transmission in anthroponotic foci.

Conclusions:

  • Leishmaniasis remains a major public health concern requiring improved control measures.
  • The development of new tools by WHO/TDR offers a pathway to scale up control activities in priority regions.
  • Effective implementation of new tools in anthroponotic foci can significantly reduce disease impact.